Identifying Biomarkers for Early Detection of Cancer in Patients With Cervical Dysplasia or Carcinoma in Situ of the Cervix
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Studying the genes expressed in samples of tissue from patients with abnormal cells may help doctors identify biomarkers related to cancer.
PURPOSE: This clinical trial is identifying biomarkers for early detection of cancer in women with cervical dysplasia or carcinoma in situ of the cervix.
| Condition |
|---|
|
Cervical Cancer Precancerous Condition |
| Study Type: | Observational |
| Official Title: | Genomics Approach to Id Novel Targets & Markers for Early Detection And Intervention In Cancer (Cervical) |
- Identify and catalogue genetic alterations and protein changes associated with developmental stages of cervical cancer [ Time Frame: Done at the completion of the study. ] [ Designated as safety issue: No ]
- Identify a ranked list of candidate genes that drive the transformation of premalignant lesions to tumors for further study and validation as molecular targets for novel early detection and treatment design [ Time Frame: Done at the completion of the study. ] [ Designated as safety issue: No ]
- Completion of genome scans at high density and analysis of gene and protein expressions to identify recurrent genetic and protein changes in cancer [ Time Frame: Done at the completion of the study. ] [ Designated as safety issue: No ]
- Changes clustered to specific chromosomal regions which harbor tumor suppressors or oncogenes [ Time Frame: Done at the completion of the study. ] [ Designated as safety issue: No ]
| Enrollment: | 80 |
| Study Start Date: | December 2004 |
| Study Completion Date: | May 2011 |
| Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
- To identify and catalogue genetic alterations and protein changes associated with developmental stages of cervical cancer.
- To identify a ranked list of candidate genes that drive the transformation of premalignant lesions to tumors for further study and validation as molecular targets for novel early detection and treatment design.
Secondary
- To complete genome scans at high density and analysis of gene and protein expression to identify recurrent genetic and protein changes in cancer.
- To confirm changes clustered to specific chromosomal regions which harbor tumor suppressors or oncogenes.
OUTLINE: Patients undergo biopsy of cervical tissue followed by loop electrocautery excision procedure (LEEP) (removing all of the tissue surrounding and under the area biopsied). RNA, DNA, and protein is extracted from the cells to provide material for the construction of libraries for Serial Analysis of Gene Expression (SAGE analysis); for hybridization against Bacterial Artificial Chromosome Comparative Genome Hybridization arrays (BAC CGH arrays); and for analysis using protein chip arrays and proteomics. Resulting data from coded samples provide gene expression and protein profiles. The coded molecular datasets are linked, analyzed, and compared using a variety of statistical software to identify putative genes, gene alterations, and proteins of interest. Some samples may be banked for future studies.
Eligibility| Ages Eligible for Study: | 19 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
All patients attending Vancouver General Hospital and referred to colposcopy for loop electrocautery excision procedure (LEEP).
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed premalignant lesion, dysplasia, or carcinoma in situ of the cervix
- Clinically documented disease
- Attending Vancouver General Hospital and referred to colposcopy for loop electrocautery excision procedure (LEEP)
PATIENT CHARACTERISTICS:
- Not pregnant
- No lack of informed consent due to language difficulty, physical and mental condition
PRIOR CONCURRENT THERAPY:
- No prior operation for removal of the cervix
- Concurrent therapy allowed
Contacts and Locations
More Information
Additional Information:
No publications provided
| Responsible Party: | British Columbia Cancer Agency |
| ClinicalTrials.gov Identifier: | NCT00601601 History of Changes |
| Other Study ID Numbers: | CDR0000581302, R01CA103830, BCCR-H04-60112, BCCR-RO4-0112 |
| Study First Received: | January 25, 2008 |
| Last Updated: | March 7, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by British Columbia Cancer Agency:
|
stage 0 cervical cancer cervical intraepithelial neoplasia grade 1 cervical intraepithelial neoplasia grade 2 cervical intraepithelial neoplasia grade 3 |
Additional relevant MeSH terms:
|
Carcinoma in Situ Uterine Cervical Neoplasms Precancerous Conditions Cervical Intraepithelial Neoplasia Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms |
Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Uterine Cervical Diseases Uterine Diseases Genital Diseases, Female |
ClinicalTrials.gov processed this record on May 19, 2013